Short Report
Hero Background

Cut through the noise.
Trade on the signal.

A weekly synthesis of institutional-grade financial reports and market mechanics.

No spam. Unsubscribe anytime.

Filters

Companies

Tickers

Authors

Latest Reports

sabizabulin Author: White Diamond Research

Part 2: New Red Flags Emerge From Veru’s Phase 3 Covid Trial, Suggesting An FDA Rejection Is Likely

White Diamond Research exposes critical flaws in Veru's COVID-19 drug trial, revealing data integrity issues, methodological problems, and potential FDA rejection risks for sabizabulin treatment

Jul 26, 2022 3 min read
VERU Author: White Diamond Research

Part 1: New Red Flags Emerge From Veru’s Phase 3 Covid Trial, Suggesting An FDA Rejection Is Likely

Veru's Sabizabulin COVID-19 drug faces potential FDA rejection due to critical Phase 3 trial design flaws, small sample size, patient selection issues, and questionable mortality data suggesting ineffective treatment

Jul 18, 2022 3 min read

The Signal. No Noise.

Join 50,000+ investors receiving our weekly synthesis.